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ABSTRACT
Introduction Achieving the Joint United Nations 
Programme on HIV and AIDS 90-90-90 targets requires 
models of HIV care that expand antiretroviral therapy 
(ART) coverage without overburdening health systems. 
Point-of-care (POC) viral load (VL) testing has the potential 
to efficiently monitor ART treatment, while enrolled 
nurses may be able to provide safe and cost-effective 
chronic care for stable patients with HIV. This study aims 
to demonstrate whether POC VL testing combined with 
task shifting to enrolled nurses is non-inferior and cost-
effective compared with laboratory-based VL monitoring 
and standard HIV care.
Methods and analysis The STREAM (Simplifying HIV 
TREAtment and Monitoring) study is an open-label, non-
inferiority, randomised controlled implementation trial. 
HIV-positive adults, clinically stable at 6 months after 
ART initiation, will be recruited in a large urban clinic 
in South Africa. Approximately 396 participants will be 
randomised 1:1 to receive POC HIV VL monitoring and 
potential task shifting to enrolled nurses, versus laboratory 
VL monitoring and standard South African HIV care. Initial 
clinic follow-up will be 2-monthly in both arms, with 
VL testing at enrolment, 6 months and 12 months. At 6 
months (1 year after ART initiation), stable participants 
in both arms will qualify for a differentiated care model 
involving decentralised ART pickup at community-based 
pharmacies. The primary outcome is retention in care 
and virological suppression at 12 months from enrolment. 
Secondary outcomes include time to appropriate entry 
into the decentralised ART delivery programme, costs per 
virologically suppressed patient and cost-effectiveness of 
the intervention compared with standard care. Findings 
will inform the scale up of VL testing and differentiated 
care in HIV-endemic resource-limited settings.
Ethics and dissemination Ethical approval has been 
granted by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BFC296/16) and University of 
Washington Institutional Review Board (STUDY00001466). 
Results will be presented at international conferences and 
published in academic peer-reviewed journals.
Trial registration NCT03066128; Pre-results.
InTRoduCTIon
Strong evidence of the beneficial effects of 
early antiretroviral therapy (ART)1–3 has led 
to WHO recommending ART for all people 
living with HIV (PLHIV).4 This aligns with 
the Joint United Nations Programme on HIV 
and AIDS (UNAIDS) 90-90-90 targets (90% 
of all PLHIV to know their status, 90% of 
these to be on ART and 90% of these to be 
virologically suppressed) to be achieved by 
the year 2020.5 In 2016, 18.2 million PLHIV 
were receiving ART globally, but another 
18.5 million still required treatment.6 Many 
health systems in low-income and middle-in-
come countries are operating at capacity 
and will struggle to provide care for more 
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Protocol
Strengths and limitations of this study
 ► This is the first randomised controlled 
implementation trial of point-of-care HIV viral load 
testing and task shifting to enrolled nurses that we 
are aware of.
 ► Point-of-care testing allows viral loads to be taken 
and acted on in one clinic visit, while enrolled nurses 
may be able to provide safe and cost-effective HIV 
care for stable patients.
 ► This strategy could lessen workloads for HIV clinics 
in low-income and middle-income countries, thereby 
increasing capacity for universal antiretroviral 
therapy coverage and viral load monitoring in line 
with Joint United Nations Programme on HIV and 
AIDS 90-90-90 targets.
 ► This is a single-site study, so results may not be 
generalisable to other settings.
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HIV-positive patients without compromising clinical 
outcomes.7 Rapid scale up of ART coverage may lead to 
several operational issues, including longer waiting times, 
ART stock-outs and human resource shortages, which 
would jeopardise achieving the 90-90-90 targets.8 Further-
more, since current models of HIV care were designed in 
the era of higher HIV-related morbidity and less tolerable 
ART regimens, many clinics may not be providing effec-
tive, patient-centred, chronic care for healthy PLHIV.9 10
In order to meet these challenges, newer models of 
chronic HIV care have been developed. These ‘differ-
entiated care models’10 11 include healthcare facility and 
community-based strategies involving elements of task 
shifting,12 less frequent clinic visits13 and/or decentralised 
ART distribution through community pharmacies or peer 
support groups.14–17 Triaging stable HIV-positive patients 
in differentiated care models requires quantitative viral 
load (VL) testing, which the WHO recommends as the 
most effective method of monitoring the response to 
ART.4 Patients with suppressed VLs may be able to receive 
less frequent follow-up visits, allowing resources to be 
redirected towards those with virological failure or other 
ongoing health needs.
Despite requiring sophisticated laboratory services, 
models suggest VL monitoring is cost-effective in Southern 
Africa when compared with CD4 count monitoring alone 
or monitoring clinical signs and symptoms.18 VL moni-
toring should be performed at 6 and 12 months after ART 
initiation and then annually according to WHO guide-
lines.4 Laboratory capacity to provide VL testing varies 
across the region, with 75% of patients on ART in South 
Africa having at least one VL performed, but only 10% in 
Uganda and 38% in Kenya.19 Rapid scale up is required to 
provide the 10 million annual VL tests that will be needed 
in Africa by the year 2020.20 21 There is growing interest in 
point-of-care (POC) VL assays,22–24 which could alleviate 
the burden on central laboratory services and improve 
clinical management by providing test results while the 
patient is still at the clinic, thereby removing the need for 
specimen transport and follow-up visits. Providing imme-
diate VL results may facilitate timely adherence inter-
ventions and, where necessary, ART regimen changes, 
thereby improving viral suppression. Modelling studies 
suggest that POC VL testing may be cost-effective when 
compared with laboratory VL testing, by improving reten-
tion and facilitating differentiated care.25 26
Several POC VL assays are already on the market or 
in development.27 28 Qualitative assays target early infant 
diagnosis and acute HIV infection, while quantitative 
assays are better suited for monitoring ART. The Cepheid 
Xpert HIV-1 VL is a fully automated, nucleic acid amplifi-
cation assay based on the GeneXpert platform (Cepheid, 
Sunnyvale, California, USA). We have validated this assay 
in our South African clinic,29 and subsequent studies in 
other Southern African settings have produced similar 
results.30–32 However, the clinical effectiveness of the 
Xpert HIV-1 VL, as well as its potential role in differenti-
ated care models, has yet to be demonstrated.
In South Africa and other African countries, enrolled 
(or associate) nurses are less highly trained than profes-
sional nurses and are cheaper to train and employ.33 34 
Despite being able to perform aspects of chronic HIV 
care, such as basic clinical assessments, counsel patients, 
perform venipuncture and operate POC tests, enrolled 
nurses currently do not have a prominent role in clin-
ical management of ART. We hypothesise that enrolled 
nurses can provide safe and cost-effective care to stable 
HIV-positive patients, while POC VL testing can improve 
management of virological failure and efficiently triage 
patients into differentiated care.
objectives
The goal of the STREAM (Simplifying HIV TREAtment 
and Monitoring) study is to demonstrate whether POC 
HIV VL testing combined with task shifting to enrolled 
nurses is non-inferior and cost-effective compared with 




The STREAM study is a single-site, open-label, two-arm, 
non-inferiority, randomised controlled implementation 
trial. HIV-positive adults who are clinically stable at 6 
months after ART initiation will be randomised 1:1 to 
receive POC VL monitoring and potential task shifting to 
enrolled nurses, versus laboratory-based VL monitoring 
and standard South African HIV care.35 The primary 
outcome is retention in care and virological suppression 
at 12 months from enrolment (see figure 1 for CONSORT 
diagram).
Study setting
The study will take place at the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA) 
eThekwini Clinical Research Site and the adjacent Prince 
Cyril Zulu Communicable Disease Clinic (PCZ CDC), a 
large public healthcare clinic in central Durban, KwaZu-
lu-Natal, South Africa. KwaZulu-Natal is a hyper-endemic 
setting with an HIV prevalence of 28% among adults 
aged 15–49.36 PCZ CDC cares for over 10 000 HIV-positive 
patients and also provides tuberculosis (TB) treatment, 
family planning, sexual health and primary care services. 
CAPRISA eThekwini Clinical Research Site conducts HIV 
treatment and prevention trials. The two clinics are situ-
ated near the main transport hub for public commuters 
in central Durban and serve a diverse, mobile population. 
PCZ CDC provides treatment in accordance with South 
African guidelines that require all PLHIV to be offered 
ART, irrespective of CD4 count, since September 2016.37 
Routine care of HIV, sexual and reproductive health, 
minor illnesses and stable non-communicable diseases 
is provided by professional nurses, with referral to a 
physician for management of virological failure, adverse 
events, opportunistic infections and poorly controlled 
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Figure 1 CONSORT diagram of the STREAM 
study. ART, antiretroviral therapy; STREAM, Simplifying HIV 
TREAtment and Monitoring.
Figure 2 Conceptual model of differentiated care in the STREAM study. ART, antiretroviral therapy; OI, opportunistic infection; 
POC, point of care; STREAM, Simplifying HIV TREAtment and Monitoring; TB, tuberculosis; VL, viral load.
non-communicable diseases. In line with South African 
national policy, PCZ CDC operates a decentralised 
differentiated care model, in which stable patients are 
referred to the Central Chronic Medicine Dispensing and 
Distribution Programme (CCMDD).37 38 This involves 
2-monthly ART collection at community pharmacies and 
6-monthly clinic visits with a professional nurse or physi-
cian (figure 2).
Eligibility criteria
HIV-positive adults, 18 years or older, who receive ART 
from PCZ CDC will be recruited when presenting for 
their first routine VL test, which is 6 months after ART 
initiation. Stable patients who plan to receive care at 
PCZ CDC for the following year and are willing and able 
to provide written informed consent will be eligible for 
enrolment. Patients who have already had their 6-month 
VL performed, are pregnant, have TB or require active 
care by a physician in accordance with South African 
guidelines39 (see online supplementary table 1) will be 
excluded from the study. These eligibility criteria are 
meant to select stable patients who are best suited to 
receive differentiated HIV care.
Randomisation
The study statistician has generated the allocation 
sequence using random numbers generated in SAS V.9.4 
(SAS Institute). Sequentially numbered, sealed, opaque 
envelopes containing intervention allocation and partici-
pant identification number have been given to the study 
clinical team, to be opened once a participant has been 
deemed eligible and is ready to be enrolled into the 
study. To ensure that the allocation sequence is followed, 
study nurses performing enrolment procedures will not 
open randomisation envelopes; this will be performed by 
the study coordinator, with subsequent checks to verify 
correct allocation.
Study procedures
At enrolment, participants will be asked to provide infor-
mation on their demographic, social and medical history, 
including age, education level, income, employment, rela-
tionship status, HIV disclosure and travel to clinic. Locally 
validated instruments to measure risk factors for viro-
logical failure will be used including the WHO Alcohol 
Use Disorder Identification Tool (AUDIT-C),40 41 WHO 
Violence Against Women Instrument (female partici-
pants only)42 43 and the Patient Health Questionnaire 2 
screen for depression.44 45
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Table 1 Schedule of evaluation in the STREAM study
Study period
Enrolment Follow-up Exit
Months in study 0 2 4 6 8 10 12




Intervention arm POC bloods VL, Cr VL, Cr, 
CD4
VL, Cr
Care provider PN EN EN PN EN* EN* PN
SOC
arm
Lab bloods VL, Cr VL, Cr, 
CD4
VL, Cr
Care provider PN PN PN PN PN* PN* PN
Demographics and social questionnaire X
Retention in care and virological 
suppression†
X
Symptom screen, vital signs, adherence 
assessment
X X X X X* X* X
Laboratory full blood count, CD4, urinalysis X X
Stored blood X X X
*No clinic visits at 8 and 10 months, if a participant was successfully referred into the community pharmacy pickup CCMDD programme at 6 
months.
†Virological suppression measured using Roche Taqman V.2.0 in both arms.
ART, antiretroviral therapy; Cr, creatinine; EN, enrolled nurse; PN, professional nurse; POC, point of care; SOC, standard of care; STREAM, 
Simplifying HIV TREAtment and Monitoring; VL, viral load.
Participants randomised to the standard of care arm 
will have laboratory-based VL, creatinine and CD4 count 
monitoring and clinical visits performed at PCZ CDC as 
scheduled in the South African Department of Health 
HIV guidelines, with laboratory results provided at their 
next clinic attendance.35 Laboratory VL and creatinine 
will be taken at enrolment, which is 6 months after ART 
initiation, with subsequent 2-monthly clinical visits by a 
professional nurse or physician (table 1). After 6 months, 
laboratory VL, creatinine and CD4 will be taken.
Participants randomised to the intervention arm will 
have the same schedule of routine blood monitoring 
performed, but using POC assays: Xpert HIV-1 VL, 
serum creatinine (Statsensor Xpress-i, Nova Biomedical, 
Waltham, Massachusetts, USA) and CD4 count (Pima, 
Alere, Waltham, Massachusetts, USA). The Statsensor 
Xpress-i46–48 and Pima49 50 have been validated in multiple 
settings and will also be validated locally as part of trial 
preparations. Use of these assays, in addition to Xpert 
HIV-1 VL, will allow patients to have all routine bloods 
drawn and results provided in the same visit. POC VL and 
creatinine will be performed at enrolment, with results 
reviewed at that visit by a professional nurse. Patients who 
are virologically suppressed and with no comorbidities will 
be referred to see an enrolled nurse at subsequent visits, 
rather than a professional nurse, which constitutes the 
task shifting component of the intervention. The enrolled 
nurse will receive training in basic HIV/TB management, 
ART and side effects, adherence counselling and appro-
priate referral systems. At 2-monthly visits, he/she will 
perform vital signs, screen for TB, assess adherence and 
issue predispensed ART packages. If the enrolled nurse 
detects symptoms or abnormal vital signs, the patient will 
be referred to a professional nurse for review at the same 
visit. After 6 months in the study, which is 1 year after ART 
initiation, a professional nurse will assess POC VL, creati-
nine and CD4 count.
decentralised ART delivery (CCMdd)
Participants in both arms who remain virologically 
suppressed, have CD4 count >200 cells/mm3 and are clin-
ically stable at 1 year after ART initiation will be referred 
into CCMDD by a professional nurse. Here they will 
receive 2-monthly community-based pharmacy pickup 
and clinic review after 6 months. Patients not eligible for 
CCMDD will continue with 2-monthly clinic visits with a 
professional nurse.
Virological failure
Management of patients with a VL of >1000 copies/mL 
will follow South African guidelines in both arms, with 
intensive adherence counselling and repeat VL testing 
after 2 months (POC Xpert HIV-1 VL in the intervention 
arm). If the repeat VL remains >1000 copies/mL and 
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Table 2 Sample size and power estimate




Rule out 75% against true intervention 85% 80% 158
Rule out 75% against true intervention 85% 90% 220
Rule out 70% against true intervention 80% 80% 396
Rule out 70% against true intervention 80% 90% 550
Rule out 72.5% against true intervention 80% 80% 704
Bold values correspond with the selected target sample size.
adherence issues have been addressed, the patient will be 
switched to standard second-line ART by a physician.
Additional laboratory investigations
Participants in both arms will have laboratory CD4 
count (FACSCalibur, BD Biosciences, San Jose, Cali-
fornia, USA), full blood count and urinalysis performed 
at enrolment and at study exit. Plasma will be drawn 
for storage at enrolment, month 6 and study exit, to 
allow retrospective HIV drug resistance testing at study 
completion.
Primary outcome
The primary outcome is a composite measure of reten-
tion in care and virological suppression at 12 months after 
study enrolment (18 months on ART). Retention in care is 
defined as collecting ART at the 12-month study visit, while 
virological suppression is defined as a VL <200 copies/mL 
using the Roche Taqman V.2.0 (Roche Diagnostics, Basel, 
Switzerland). This assay will be used in both arms at 12 
months to allow direct comparison.
Secondary outcomes
Secondary outcomes comparing standard of care and 
intervention arms are the following:
 ► Proportion with HIV VL <200 copies/mL at 12 months 
after enrolment.
 ► Proportion retained in care at 12 months after 
enrolment.
 ► Proportion appropriately retained on same ART 
regimen throughout study duration.
 ► Mean change in CD4 count from enrolment to 
12-month study exit visit.
 ► Costs incurred per patient and per patient virologi-
cally suppressed and retained in care.
 ► Time to detection of virological failure, subsequent 
intensive adherence counselling and initiation of 
second-line regimen.
 ► Proportion of lost to follow-up or deceased (estab-
lished using hospital records, death certificate and 
family verbal report).
 ► Proportion of patients entered appropriately into 
CCMDD and time to appropriate entry into CCMDD.
 ► Mean number of clinical visits per patient.
Sample size
The sample size and power calculation are based on 
determining non-inferiority of the intervention arm 
(table 2). Based on the clinic’s historical performance, 
80% of adults in the standard of care arm will be viro-
logically suppressed and retained at 12 months. With a 
non-inferiority margin of −10%, which would be accept-
able if the intervention is less costly, a trial of 198 partici-
pants per arm will have 80% power with the lower limit of 
a one-sided 95% CI to declare non-inferiority.
Recruitment
Recruitment of approximately 396 participants is planned 
over 6 months, requiring a minimum of 3 participants per 
working day. Study information in the form of leaflets and 
short presentations will be presented to patients in the PCZ 
CDC waiting area. Clinic staff will be trained regarding 
study procedures, eligibility criteria and how to refer 
eligible patients for screening. If necessary, study staff will 
also actively recruit interested patients in the clinic waiting 
area.
Retention activities
Participants in both arms who are more than 2 weeks late 
for a scheduled clinic or community pharmacy visit will 
receive one attempt at telephonic follow-up, as per South 
African guidelines.35 Community pharmacies will inform 
PCZ CDC of participants in CCMDD who are more than 
2 weeks late for ART collection. These participants will be 
removed from CCMDD and will need to return to CDC for 
ART collection and adherence counselling where necessary.
data collection and management
Clinical data including ART regimen changes, entry into 
CCMDD, new clinical diagnoses and receipt of intensive 
adherence counselling will be collected during study 
clinic visits or clinical chart review. Data will be captured by 
study staff using laptops and standardised electronic case 
report forms in the iDataFax system (DF/Net Research, 
Seattle, USA). All data entry will undergo three stages of 
quality control including immediate source document 
review, internal quality audits and weekly quality reports 
generated by iDataFax.
Statistical methods
A descriptive analysis of baseline sociodemographic vari-
ables will be used to assess comparability of the two study 
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arms. The primary analysis will estimate the absolute 
difference in proportions achieving the primary outcome 
between the intervention and control arms, assessed using 
the χ2 test. For binary secondary outcomes, the absolute 
difference in proportions will be assessed using the χ2 test. 
For continuous secondary outcomes, means in each arm 
will be compared using the unpaired Student’s t-test. We 
will perform bivariate and multivariable logistic regres-
sion to identify independent risk factors for reaching 
the primary outcome. Each covariate will be assessed for 
statistical significance in a bivariate logistic regression. 
Potential risk factors that have been identified in the liter-
ature (eg, age, sex51) will also be assessed as covariates in a 
multivariable regression. Data will be analysed using SAS 
and R (R Foundation for Statistical Computing).
Secondary costing analysis
An activity-based micro-costing approach will be used to 
estimate the cost per patient and per patient virologically 
suppressed and retained in care in the intervention arm 
compared with the standard of care arm. Time and motion 
studies, observing multiple staff members over several 
visits, will allow an estimation of the average time taken 
to complete each step of the clinic visit (VL testing, clin-
ical assessment, counselling) for both study arms. Time 
spent on research purposes (eg, data collection) will be 
noted separately from time spent on clinical care. Stan-
dardised activity-based cost menus will be used to collect 
site costs, including start-up costs, human resources, 
supplies, VL test costs and other expenses. When data are 
not available from our cohort, we will use data from popu-
lation-based South African studies. Additional cost data 
may be obtained from health facilities, published govern-
ment information on labour costs and health economics 
literature. Analyses will follow the guidelines for costing 
HIV interventions52 and will reflect the provider perspec-
tive. Costs will be categorised as fixed or variable. Variable 
costs indicate which costs could change (eg, less expen-
sive POC HIV VL assay) and influence the estimates from 
the study. We will also collect data on costs incurred by 
participants, to determine whether POC VL testing is 
cost-effective from a patient and societal perspective. 
The micro-costing data, time and motion studies and 
clinical outcomes will be used to estimate the average 
cost per HIV-positive patient achieving viral suppression 
and retained in care in the intervention arm compared 
with standard of care. Furthermore, these data will 
allow process evaluation of the mechanism by which the 
different components of the intervention (POC testing 
and enrolled nurses) contribute to the achievement of 
study outcomes, including costs saved and incurred.
EThICS, MonIToRIng And dISSEMInATIon
The trial has been approved by the University of 
KwaZulu-Natal Biomedical Research Ethics Committee 
(BFC296/16) and the University of Washington Institu-
tional Review Board (STUDY00001466). Permission to 
conduct the study in the PCZ CDC was provided by the 
eThekwini Municipality Health Unit. Eligible patients 
will be asked to provide written informed consent for 
study procedures and sample storage. All participants will 
receive a small financial compensation (ZAR 100, approx-
imately US$7.5) for their time, transport and inconve-
nience after each study visit in accordance with South 
African Research Council Guidelines.53 A data monitoring 
committee is not required as the risk of significant harms 
from study procedures is low. Any breaches in confidenti-
ality, study protocol or adverse events attributable to this 
study will be reported to the above institutional review 
boards. Results will be presented at national and interna-
tional conferences and published in academic, peer-re-
viewed journals.
Trial status
The trial was registered on  clinicaltrials. gov 
(NTC03066128) on 22 February 2017. Enrolment started 
on 24 February 2017 and is predicted to be completed in 
August 2017.
dISCuSSIon
New models of HIV care are urgently required if the 
UNAIDS 90-90-90 targets are to be reached. To our knowl-
edge, this is the first randomised controlled trial investi-
gating a combined intervention of POC HIV VL testing 
and task shifting. If clinically effective and affordable, this 
strategy may contribute to the successful scale up of VL 
monitoring and ART coverage. The STREAM study will 
also generate much needed real-world data to improve 
mathematical models of VL testing strategies.18 25
Results from this study of the Xpert HIV-1 VL may be 
applicable to other quantitative POC VL assays on the 
market with similar performance characteristics. The 
SAMBA I/II semi-Q (Diagnostics for the Real World, 
Cambridge, United Kingdom),54 Liat (Roche Diagnostics, 
Basel, Switzerland)55 and Alere Q NAT (Alere, Waltham, 
Massachusetts, USA)56 have all been evaluated in 
Southern Africa, each with strengths and limitations. The 
Xpert HIV-1 VL is limited by the need for centrifuging 
blood samples to obtain plasma and a 90 min processing 
time. While Cepheid is working to address both of these 
issues, the widespread use of the GeneXpert platform for 
TB diagnostics means that the Xpert HIV-1 VL is partic-
ularly amenable to rapid scale up in several low-income 
and middle-income countries.57
The STREAM study design incorporates two forms of 
differentiated care: task shifting to enrolled nurses in 
the intervention arm and community ART collection 
for stable participants in both arms. Task shifting ART 
provision from physician-led secondary care services to 
nurses in primary care facilities has been successfully 
implemented in Southern Africa.58 59 We hypothesise that 
further task shifting from professional to enrolled nurses 
may be a cost-effective and gentler ‘step down’ prior to 
community ART collection and that POC VL testing will 
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allow more effective triage into community ART collec-
tion programme.14 16 17 38 Removing the need to reattend 
for VL results could decrease clinic visits within these 
programme by 33%–50%.
A limitation of our clinical implementation trial is the 
relatively small sample size and conducting the study at 
a single site. The diverse population and urban setting 
of the trial may mean that results are not generalisable 
across all parts of Southern Africa. Nevertheless, findings 
from STREAM may be used to design POC VL studies in 
other priority populations and settings, including those 
with high incidence of virological failure (eg, adolescents) 
and rural areas with limited laboratory access. A second 
limitation may be that financial compensation provided 
in the study could increase retention in care compared 
with non-study settings. However, the reimbursements 
are relatively small and will be offered to all participants, 
so are unlikely to impact on comparisons of the primary 
outcome between arms.
Achieving the 90-90-90 targets requires a large and rapid 
scale up of HIV VL monitoring, as well as strategies that 
make HIV programme more efficient and facilitate reten-
tion in care. The STREAM study will provide evidence as 
to whether POC VL testing within a differentiated care 
model can help achieve these goals.
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